Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

12.95EUR
11:35am EDT
Change (% chg)

€0.29 (+2.33%)
Prev Close
€12.65
Open
€12.65
Day's High
€12.95
Day's Low
€12.48
Volume
238,992
Avg. Vol
123,825
52-wk High
€13.20
52-wk Low
€8.21

Latest Key Developments (Source: Significant Developments)

Ablynx lowers net cash burn guidance for the full year 2017
Thursday, 24 Aug 2017 01:00am EDT 

Aug 24 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE.H1 REVENUES OF €34.7 MILLION (2016: €53.1 MILLION).H1 OPERATING LOSS OF €24.8 MILLION (2016: €2.0 MILLION).H1 NET CASH BURN OF €30.9 MILLION (2016: €19.0 MILLION).H1 CASH POSITION OF €204.5 MILLION (2016: €288.7 MILLION).ON TRACK TO REPORT TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB IN PATIENTS WITH ATTP IN LATE Q3 2017.EXPECTS TO REPORT RESULTS OF ONGOING SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS BEFORE END OF YEAR.IN Q4 2017, CO PLANS TO FILE FOR REGULATORY APPROVAL TO ENABLE A PHASE II STUDY IN JAPAN WITH ALX-0171 IN INFANTS HOSPITALISED WITH A RSV INFECTION.COMPANY IS LOWERING ITS NET CASH BURN GUIDANCE FOR THE FULL YEAR 2017 AND IT IS NOW EXPECTED TO BE IN THE RANGE OF €65-75 MILLION.IN Q4 2017, WILL ALSO FILE FOR REGULATORY APPROVALS TO ENABLE GLOBAL PHASE II STUDY WITH ALX-0171 IN ADULTS WHO UNDERWENT STEM CELL TRANSPLANTATION AND BECAME INFECTED WITH RSV.  Full Article

Ablynx announces warrant exercise
Friday, 11 Aug 2017 01:00am EDT 

Aug 11 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES WARRANT EXERCISE.AS A RESULT OF THIS TRANSACTION, ABLYNX NOW HAS 61,169,732 SHARES OUTSTANDING.ADDITIONAL 16,700 COMMON SHARES HAVE BEEN ISSUED BY COMPANY IN EXCHANGE FOR EUR 80,684 AS RESULT OF EXERCISE OF WARRANTS​.  Full Article

Ablynx receives FDA fast track designation for Caplacizumab
Wednesday, 26 Jul 2017 01:00am EDT 

July 26 (Reuters) - ABLYNX NV :ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP.ABLYNX NV - ‍CAPLACIZUMAB IS CURRENTLY BEING FURTHER EVALUATED IN PHASE III HERCULES STUDY​.ABLYNX NV - ‍RESULTS FROM THIS PHASE III STUDY WILL BE REPORTED IN SECOND HALF OF 2017​.  Full Article

Ablynx issues additional 19,833 common shares
Monday, 24 Jul 2017 01:00am EDT 

July 24 (Reuters) - ABLYNX NV ::ADDITIONAL 19,833 COMMON SHARES HAVE BEEN ISSUED BY COMPANY IN EXCHANGE FOR EUR 121,444 AS RESULT OF EXERCISE OF WARRANTS.  Full Article

Ablynx and Sanofi enter into a strategic collaboration
Thursday, 20 Jul 2017 01:13am EDT 

July 20 (Reuters) - ABLYNX NV : :ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES.ABLYNX NV - ‍COLLABORATION GIVES SANOFI ACCESS TO CERTAIN NANOBODIES IN ABLYNX'S EXISTING PORTFOLIO​.ABLYNX NV - ‍SANOFI GAINS EXCLUSIVE GLOBAL RIGHTS TO CERTAIN MULTI-SPECIFIC NANOBODIES AGAINST SELECTED TARGETS​.ABLYNX NV - ‍FINANCIAL TERMS INCLUDE AN UPFRONT PAYMENT OF EUR 23 MILLION TO ABLYNX​.ABLYNX NV - ‍ABLYNX WILL RECEIVE RESEARCH FUNDING, ESTIMATED TO AMOUNT TO EUR 8 MILLION FOR INITIALLY SELECTED TARGETS​.  Full Article

Ablynx initiates study of caplacizumab in healthy Japanese subjects
Monday, 26 Jun 2017 01:00am EDT 

June 26 (Reuters) - Ablynx NV ::ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS.ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS.TO COMPARE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILES OF CAPLACIZUMAB IN JAPANESE AND CAUCASIAN SUBJECTS.TO EVALUATE IMMUNOGENICITY OF CAPLACIZUMAB IN JAPANESE SUBJECTS.  Full Article

Ablynx to receive 15 million euros milestone payment
Monday, 22 May 2017 01:00am EDT 

May 22 (Reuters) - ABLYNX NV ::NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT.ABLYNX ANNOUNCED THAT IT HAS COMPLETED PREPARATION OF A PRE-CLINICAL PACKAGE FOR A NOVEL NANOBODY® (ALX-1141) IN OSTEOARTHRITIS.AS PART OF ONGOING COLLABORATION BETWEEN ABLYNX AND MERCK KGAA <<>>, MERCK HAS ACCEPTED PRE-CLINICAL PACKAGE AND THIS HAS TRIGGERED A EUR 15 MILLION MILESTONE PAYMENT TO ABLYNX.MERCK IS NOW RESPONSIBLE FOR FURTHER CLINICAL DEVELOPMENT OF MOLECULE.  Full Article

Ablynx Q1 revenues eur 9.1 million (2016 eur 27.4 million)
Thursday, 11 May 2017 01:03am EDT 

May 11 (Reuters) - ABLYNX NV ::Q1 REVENUES EUR 9.1 MILLION (2016: EUR 27.4 MILLION).Q1 OPERATING LOSS OF EUR 20.2 MILLION (2016: LOSS EUR 0.7 MILLION).COMPANY REITERATES ITS NET CASH BURN GUIDANCE FOR FULL-YEAR 2017 TO BE IN RANGE OF EUR 75-85 MILLION..FINANCIAL GUIDANCE AND 2017 OUTLOOK CONFIRMED.Q1 NET CASH OUTFLOW OF EUR 26.2 MILLION (2016: EUR 2.5 MILLION).EXPECTS TO COMMUNICATE TOPLINE RESULTS FROM PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ATTP IN SECOND HALF OF 2017.Q1 EUR 209.2 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND SHORT-TERM INVESTMENTS (2016: EUR 233.7 MILLION).DATA ARE EXPECTED TO BE USED TO SUPPORT RECENTLY SUBMITTED MAA IN EUROPE AND PLANNED BIOLOGICS LICENSE APPLICATION FILING IN USA IN 2018.  Full Article

Ablynx announces warrant exercise
Friday, 21 Apr 2017 01:02am EDT 

April 21 (Reuters) - Ablynx NV ::Announces warrant exercise.An additional 57,125 common shares have been issued by company in exchange for EUR 398,801.77 ($427,395.86) as result of exercise of warrants.As a result of this transaction, co now has 61,133,199 shares outstanding.  Full Article

Ablynx FY revenue rises 10 pct
Thursday, 23 Feb 2017 01:00am EST 

Ablynx Nv : FY total revenues of EUR 85.2 million (+10%) . FY cash position of EUR 235.4 million . FY net cash burn of EUR 72.2 million, in line with previously guided range of EUR 65-75 million . FY net loss EUR 1.1 million versus loss of EUR 54.5 million year ago .FY operating loss EUR 28.6 million versus loss of EUR 17.6 million year ago.  Full Article

BRIEF-Ablynx lowers net cash burn guidance for the full year 2017

* ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE